These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 1712746)

  • 1. Tachykinins in the rat substantia nigra: effects of selective dopamine receptor antagonists.
    Oblin A; Zivkovic B
    Fundam Clin Pharmacol; 1991; 5(2):129-38. PubMed ID: 1712746
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of haloperidol and clozapine on preprotachykinin-A messenger RNA, tachykinin tissue levels, release and neurokinin-1 receptors in the striato-nigral system.
    Humpel C; Knaus GA; Auer B; Knaus HG; Haring C; Theodorsson E; Saria A
    Synapse; 1990; 6(1):1-9. PubMed ID: 1697986
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective antagonists of dopamine receptor subtypes differentially affect substance P levels in the striatum and substantia nigra.
    Oblin A; Zivkovic B; Bartholini G
    Brain Res; 1987 Sep; 421(1-2):387-90. PubMed ID: 2446703
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitative radioimmunocytochemical evidence that haloperidol and SCH 23390 induce opposite changes in substance P levels of rat substantia nigra.
    Cruz CJ; Beckstead RM
    Brain Res; 1988 Aug; 457(1):29-43. PubMed ID: 2458801
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Subchronic haloperidol treatment decreases the in vivo release of tachykinins in rat substantia nigra.
    Lindefors N; Brodin E; Ungerstedt U
    Eur J Pharmacol; 1989 Feb; 161(1):95-8. PubMed ID: 2470596
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dopamine antagonist haloperidol decreases substance P, substance K, and preprotachykinin mRNAs in rat striatonigral neurons.
    Bannon MJ; Lee JM; Giraud P; Young A; Affolter HU; Bonner TI
    J Biol Chem; 1986 May; 261(15):6640-2. PubMed ID: 2422168
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 3H-SCH 23390 binding sites in the rat substantia nigra: evidence for a presynaptic localization and innervation by dopamine.
    Porceddu ML; Giorgi O; Ongini E; Mele S; Biggio G
    Life Sci; 1986 Jul; 39(4):321-8. PubMed ID: 3526066
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro and in vivo release of neurokinin A-like immunoreactivity from rat substantia nigra.
    Diez-Guerra FJ; Sirinathsinghji DJ; Emson PC
    Neuroscience; 1988 Nov; 27(2):527-36. PubMed ID: 2905788
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neurotensin-dopamine interactions in the substantia nigra of the rat brain.
    Merchant KM; Bush LG; Gibb JW; Hanson GR
    J Pharmacol Exp Ther; 1990 Nov; 255(2):775-80. PubMed ID: 2147039
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tachykinin neurokinin-1 and neurokinin-3 receptor-mediated responses in guinea-pig substantia nigra: an in vitro electrophysiological study.
    Nalivaiko E; Michaud JC; Soubrié P; Le Fur G; Feltz P
    Neuroscience; 1997 Jun; 78(3):745-57. PubMed ID: 9153655
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Haloperidol-induced reduction of nigral substance P-like immunoreactivity: a probe for the interactions between dopamine and substance P neuronal systems.
    Hanson GR; Alphs L; Wolf W; Levine R; Lovenberg W
    J Pharmacol Exp Ther; 1981 Aug; 218(2):568-74. PubMed ID: 6166743
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Involvement of the D-2 dopamine receptor in the neuroleptic-induced decrease in nigral substance P.
    Oblin A; Zivkovic B; Bartholini G
    Eur J Pharmacol; 1984 Oct; 105(1-2):175-7. PubMed ID: 6208042
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute effects of D-1 and D-2 dopamine receptor agonist and antagonist drugs on basal ganglia [Met5]- and [Leu5]-enkephalin and neurotensin content in the rat.
    Taylor MD; de Ceballos ML; Jenner P; Marsden CD
    Biochem Pharmacol; 1991 May; 41(9):1385-91. PubMed ID: 1673340
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tissue levels and in vivo release of tachykinins and GABA in striatum and substantia nigra of rat brain after unilateral striatal dopamine denervation.
    Lindefors N; Brodin E; Tossman U; Segovia J; Ungerstedt U
    Exp Brain Res; 1989; 74(3):527-34. PubMed ID: 2468514
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuroleptic treatment induces region-specific changes in levels of neurokinin A and substance P in rat brain.
    Lindefors N; Brodin E; Ungerstedt U
    Neuropeptides; 1986 Apr; 7(3):265-80. PubMed ID: 2423911
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Substance P and neurokinin A regulate by different mechanisms dopamine release from dendrites and nerve terminals of the nigrostriatal dopaminergic neurons.
    Baruch P; Artaud F; Godeheu G; Barbeito L; Glowinski J; Chéramy A
    Neuroscience; 1988 Jun; 25(3):889-98. PubMed ID: 2457187
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Striatal tachykinin biosynthesis: regulation of mRNA and peptide levels by dopamine agonists and antagonists.
    Bannon MJ; Elliott PJ; Bunney EB
    Brain Res; 1987 Dec; 427(1):31-7. PubMed ID: 2448008
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intranigral substance P stimulation of striatal dopamine release is inhibited by spantide II: a new tachykinin antagonist without apparent neurotoxicity.
    Reid MS; Hökfelt T; Herrera-Marschitz M; Håkanson R; Feng DM; Folkers K; Goldstein M; Ungerstedt U
    Brain Res; 1990 Nov; 532(1-2):175-81. PubMed ID: 1704289
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intranigral injection of selective neurokinin-1 and neurokinin-3 but not neurokinin-2 receptor agonists biphasically modulate striatal dopamine metabolism but not striatal preprotachykinin-A mRNA in the rat.
    Humpel C; Saria A
    Neurosci Lett; 1993 Jul; 157(2):223-6. PubMed ID: 7694197
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative effects of chronic haloperidol and sulpiride treatment on nigral and striatal GABA content.
    Nicoletti F; Patti F; Condorelli DF; Rampello L; Giammona G; Di Giorgio RM; Canonico PL; Scapagnini U
    J Neurochem; 1981 Oct; 37(4):1048-51. PubMed ID: 7320718
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.